Why carry out this study?

The number of hepatitis C patients is increasing globally, and hepatitis C disease and its complications are also a major health burden. Affordable pan-genotype treatment options remain an unmet medical need for patients with chronic hepatitis C in China.

Most of the approved direct-acting antiviral (DAA) drugs in China are specifically used for the treatment of HCV GT-1, and the accessibility of DAA drugs for GT2, GT3, and GT6 patients in China remains to be resolved.

This clinical study confirmed the efficacy and safety of alfosbuvir combined with daclatasvir for 12 weeks in adult patients with chronic hepatitis C, which may provide a new treatment option for liver cancer patients in China.

What was learned from this study?

Alfosbuvir combined with daclatasvir for 12 weeks showed good efficacy in patients with chronic hepatitis C of genotype 1, 2, 3, and 6, with a sustained virological response rate of > 95%. In particular, patients with GT-2 hepatitis C were more sensitive to the study drug, and the sustained virological response rate reached 100%.

The efficacy of the alfosbuvir combination regimen is not affected by cirrhosis status, prior interferon therapy, or baseline NS5A and/or NS5B RAS, and it has a good clinical safety profile.